Table: Santen Pharm -Q1 group results (IFRS)

SANTEN PHARMACEUTICAL

07/08/2025 07:34

Aug 7 (Reuters)- 
              Santen Pharmaceutical Co Ltd 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                   3 months ended      3 months ended       Year to 
                  Jun 30, 2025        Jun 30, 2024     Mar 31, 2026 
                     LATEST             YEAR-AGO          COMPANY   
                     RESULTS             RESULT          FORECAST   
  Sales               68.74               74.77           294.00    
                   (-8.1 pct)          (+3.3 pct)       (-2.0 pct)  
  Operating            7.57               13.16            44.00    
                   (-42.4 pct)         (+3.2 pct)       (-6.1 pct)  
  Pretax
  Net                  5.88               10.63            34.00    
                   (-44.7 pct)         (+2.1 pct)       (-6.2 pct)  
  EPS Basic         17.32 yen           29.59 yen       102.66 yen  
  EPS Diluted       17.28 yen           29.50 yen                   
  Ann Div                               36.00 yen        38.00 yen  
  -Q2 Div                               17.00 yen        19.00 yen  
  -Q4 Div                               19.00 yen        19.00 yen  
 
  NOTE - Santen Pharmaceutical Co Ltd. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company. 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4536.T